- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Kaakour on the Rationale For Evaluating Genomic Testing Patterns in Prostate Cancer
January 26th 2024, 9:10pm
Genitourinary Cancers Symposium (ASCO GU)
Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.
Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model
January 26th 2024, 8:16pm
Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.
Dr Smith on the Predictive Value of CA-125 KELIM Score for Outcomes With HIPEC in Ovarian Cancer
January 26th 2024, 8:16pm
Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.
CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery
January 26th 2024, 7:42pm
Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.
Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer
January 26th 2024, 7:05pm
Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.
Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies
January 26th 2024, 7:00pm
Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.
Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer
January 26th 2024, 6:35pm
Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.
Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer
January 26th 2024, 4:12pm
Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.
Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer
January 26th 2024, 3:54pm
Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.
Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies
January 26th 2024, 3:51pm
Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.
Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC
January 25th 2024, 11:45pm
Genitourinary Cancers Symposium (ASCO GU)
A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.
Real-World Findings Emphasize the Need for Early Genetic Testing in HRR-Mutated mCRPC
January 25th 2024, 11:25pm
Genitourinary Cancers Symposium (ASCO GU)
Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.
Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC
January 25th 2024, 11:16pm
Genitourinary Cancers Symposium (ASCO GU)
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
Long-Term ADT Plus High-Dose Radiation Provides Survival Advantage in High-Risk Prostate Cancer
January 25th 2024, 9:20pm
Genitourinary Cancers Symposium (ASCO GU)
Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.
Neoadjuvant Darolutamide/ADT Followed By Radical Prostatectomy Is Safe/Effective in Localized Prostate Cancer
January 25th 2024, 8:36pm
Genitourinary Cancers Symposium (ASCO GU)
Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.
Abiraterone Acetate/Prednisone/Apalutamide Maintains HRQOL Outcomes in Prostate Cancer
January 25th 2024, 8:25pm
Genitourinary Cancers Symposium (ASCO GU)
Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.
Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC
January 25th 2024, 8:16pm
Genitourinary Cancers Symposium (ASCO GU)
A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.
Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC
January 25th 2024, 7:35pm
Genitourinary Cancers Symposium (ASCO GU)
Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.
Underutilization of HRR Mutation Testing in Clinic Signals Unmet Need in mCRPC
January 25th 2024, 7:26pm
Genitourinary Cancers Symposium (ASCO GU)
Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.
Prior EBRT Shows No Correlation With Hematologic Toxicity in Patients With mCRPC Treated With Ra-223
January 25th 2024, 6:30pm
Genitourinary Cancers Symposium (ASCO GU)
Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.